Skip to content

Clinical observation on patients with ST-segment elevation myocardial infarction after injection of recombinant human prourokinase into coronary artery

Clinical observation on patients with ST-segment elevation myocardial infarction after injection of recombinant human prourokinase into coronary artery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045892
Enrollment
Unknown
Registered
2021-04-27
Start date
2018-03-01
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-segment elevation myocardial infarction

Interventions

Experimental group:recombinant human prourokinase
Control group:nothing

Sponsors

The Second Affiliated Hospital of Inner Mongolia University of Science and Technology Baotou Medical College
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All selected patients met the diagnostic criteria for acute ST-segment elevation myocardial infarction in the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction: 1. There are obvious symptoms of myocardial ischemia; 2. Newly-appearing or suspected to be newly-appearing obvious ST-T changes on the ECG or newly-appearing left bundle branch block, and newly-appearing pathological Q waves; 3. Changes in the concentration of myocardial injury markers.

Exclusion criteria

Exclusion criteria: 1. Recent history of bleeding, trauma, visceral surgery and cerebral hemorrhage, etc.; 2. There is severe liver and kidney dysfunction; 3. Combined tumor; 4. People with bleeding tendency or bleeding diseases; 5. Those who are allergic to research drugs and iodine; 6. Patients during pregnancy; 7. Those with severe hypertension (>= 180/110mmHg) and acute heart failure that are difficult to control; 8. Those who underwent coronary stent implantation or coronary artery bypass graft in the past; 9. Those who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
ST resolution;Left Ventricular Ejection Fractions, LVEF;left ventricular end-diastolic dimension, LVDD;major adverse cardiovascular events;

Countries

China

Contacts

Public ContactWang Zichao

The Second Affiliated Hospital of Inner Mongolia University of Science and Technology Baotou Medical College

wzch721030@163.com+86 15847219898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026